Navigation Links
Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment
Date:11/7/2007

- Renal Solutions Announces Opportunity for Patients to Participate in

Research Aiming Toward Improved Future Dialysis Options -

WARRENDALE, Pa., Nov. 7 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services, today announced that a home use clinical research trial has begun using sorbent technology. The study presents the opportunity for 25 dialysis study participants to evaluate the ability to self-administer extended duration dialysis in the home when using the Allient(R) Sorbent Hemodialysis System. In this study, the use of the Allient System in the home is an investigational use.

The Allient System enables hemodialysis using only 1.5 gallons (6 liters) of drinking water to provide a convenient therapy option requiring no plumbing modifications to a person's home. It is the only system that uses Sorbent Management for Advanced Renal Replacement Therapy (SMARRT(TM)). SMARRT therapy is based on more than 35 years of proven dialysis, using a gentle, patient-driven technology that enables flexible treatment options including extended duration dialysis therapy -- resulting in greater patient freedom and control.

"Our current participating clinical trial sites demonstrate their commitment to improving future patients' quality of life by taking part in a study like this," said David Vanella, Renal Solutions Vice President of Regulatory Affairs. "It's the drive to discover and apply new technologies that ultimately makes future alternative therapies available and accessible to patients."

The success of this trial may permit dialysis providers in the future to offer an alternative system and therapeutic modality to their patients. In the trial, study participants are trained and transitioned during the initial 8 weeks from self-care in a dialysis clinic setting to 8 weeks of dialysis self- administration in the home.

"Extended duration dialysis in the home is not a new concept and its potential benefits are well-known, including increased stamina, enhanced appetite and improved quality of life as just a few of the improvements this form of treatment can offer," said Renal Solutions CEO Peter M. DeComo. "The home modality has been out of vogue in part because available dialysis equipment hasn't been suited to the home. But it's on its way back. This trial may mark a tremendous step forward for people living with chronic kidney failure in the future."

"In addition to home hemodialysis being a proven alternative to in-center dialysis, at-home dialysis offers individuals more freedom and control in their lives," said Dr. Mark Rohrscheib, University of New Mexico Health Sciences Center. "The convenience of a dialysis technology that uses only a small amount of drinking water for each treatment is a tremendous advantage for home dialysis. Patients interested in new modalities will be excited to learn about this trial."

"We're pleased to be part of a trial that may introduce new options for our home dialysis patients," said Brigitte Schiller, MD, Director of Research, Satellite Healthcare, Mountain View, Ca. "This trial may further bring to light the benefits of extended duration dialysis."

Active recruitment has begun at multiple sites with subjects continuing to enroll in the study. Renal Solutions is working with a group of nephrologists and patient-focused dialysis facilities to conduct this trial. Individuals who are interested in contributing to a movement that is intended innovate the way chronic kidney failure is treated should ask their doctors about participating local research sites.

Patient-focused dialysis centers with certified home programs that are interested in learning more about this home trial should contact Mr. Vanella, (724) 772-6900, ext. 140.

About Renal Solutions, Inc.

Renal Solutions, Inc., a medical device and healthcare service company, is commercializing the Allient(R) Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System, brings SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) therapy to the dialysis field, opening new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased flexibility and convenience benefits.


'/>"/>
SOURCE Renal Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clinical trials present better alternatives for dialysis patients
2. Nighttime Home Dialysis a Boon for Kidney Patients
3. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
4. WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA
5. New peritoneal dialysis diagnostic discovered
6. Early intervention dramatically improves outcomes for new dialysis patients
7. Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date
8. Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
9. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
10. DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead
11. Radiologists encouraged to look beyond cancer for clinically unseen diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
(Date:2/10/2016)... ... 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain ... Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... date is March 16, 2016. A free review copy is available to the ...
(Date:2/10/2016)... West Palm Beach, Florida (PRWEB) , ... February ... ... Golf & Country Club) announced that it has been awarded the prestigious Distinguished ... of the World award program conducted by BoardRoom magazine, one of the most ...
(Date:2/10/2016)... Middleboro, MA (PRWEB) , ... February 10, 2016 ... ... of their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns ... to provide a solution that ensures the integrity of biological samples while operating ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Feb. 10, 2016  CVS Health (NYSE: CVS ... in Santa Clara County, CA , ... the Santa Clara University campus. CVS Pharmacy stores and ... patients against the disease. Students at Santa Clara University ... vaccinated. In addition, anyone who has had close contact ...
(Date:2/10/2016)... Feb. 10, 2016 Immune Pharmaceuticals Inc. (NASDAQ: ... today that it has filed a patent application directed ... cancers. --> --> ... administration of Ceplene (histamine dihydrochloride) in combination with immune ... predicting the efficacy of Ceplene and IL-2 therapy in ...
(Date:2/10/2016)... TOKYO , Feb. 10, 2016  Astellas Pharma ... , "Astellas") announced today that it has successfully completed, ... a tender offer to purchase all issued and outstanding ... OCAT, President and CEO: Paul Wotton , "Ocata") ... the stockholder in cash ("Tender Offer"). Astellas commenced the ...
Breaking Medicine Technology: